NCT03911076View on ClinicalTrials.gov

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 22, 2019

Primary Completion Date

June 8, 2022

Study Completion Date

June 8, 2022

Conditions
ASC-USASC-HLSIL
Interventions
BIOLOGICAL

PVX-2

pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)

OTHER

Placebo

PBS and PGC

Trial Locations (6)

33458

Health Awareness, Inc., Port Saint Lucie

45014

Obstetrics & Gynecology Associates, Inc., Fairfield

75062

MacArthur Medical Center, Irving

78412

Corpus Christi Women's Clinic (Elligo Health Research, Inc.), Corpus Christi

78758

Austin Area Obstetrics, Gynecology, and Fertility, Austin

07103

University Hospital, Rutgers New Jersey Medical School, Newark

Sponsors

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

PapiVax Biotech, Inc.

OTHER